INKT - MiNK Therapeutics gains with bullish calls from analysts on cell therapy platform

Several Wall Street analysts have initiated their coverage on MiNK Therapeutics (INKT +6.1%) with Buy equivalent ratings driving the stock higher for the second consecutive session. B. Riley Securities' analyst Kalpit Patel argues that the company’s invariant natural killer T (iNKT) cell therapies offer it a competitive advantage in the crowded field of cell therapies. Patel begins the coverage with a Buy rating, and the price target of $24 per share indicates a premium of ~27% to the last close. Meanwhile, Baird’s Jack Allen with an Outperform rating on the stock highlights the “strong” therapeutic potential of iNKT cells “given their natural allogeneicity and proven cell killing ability.” “With clinical readouts in at least four indications expected over the coming ~12 months, MiNK has a number of ways to win," he added. The price target of $26 implies a premium of ~37% to the last close. In addition, William Blair

For further details see:

MiNK Therapeutics gains with bullish calls from analysts on cell therapy platform